SAN FRANCISCO (AP) — Audentes Therapeutics Inc. (BOLD) on Thursday reported a loss of $24.4 million in its fourth quarter.
On a per-share basis, the San Francisco-based company said it had a loss of 82 cents.
The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 92 cents per share.
For the year, the company reported that its loss widened to $90.2 million, or $3.40 per share.
Audentes Therapeutics shares have climbed 5.5 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $32.97, more than doubling in the last 12 months.